Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. 더 보기
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -7.67 | -15.0009778995 | 51.13 | 51.13 | 42.85 | 456868 | 45.39534473 | CS |
4 | -8.99 | -17.1401334604 | 52.45 | 63.5 | 42.85 | 402891 | 53.10594023 | CS |
12 | -6.66 | -13.2881085395 | 50.12 | 63.5 | 42.85 | 420877 | 53.68661233 | CS |
26 | -5.83 | -11.8279569892 | 49.29 | 63.5 | 36.26 | 413480 | 48.44521283 | CS |
52 | 25.49 | 141.847523651 | 17.97 | 72.29 | 16.39 | 470660 | 48.97831978 | CS |
156 | 21.96 | 102.139534884 | 21.5 | 72.29 | 14.19 | 432979 | 43.09401475 | CS |
260 | 21.96 | 102.139534884 | 21.5 | 72.29 | 14.19 | 432979 | 43.09401475 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관